美股市场个股详情
MNKD 曼恩凯德生物医疗
- 7.440
- +0.180+2.48%
收盘价 11/06 16:00 (美东)
- 7.460
- +0.020+0.27%
盘后 19:51 (美东)
20.46亿总市值148.80市盈率TTM
7.630最高价7.261最低价368.01万股成交量7.340今开7.260昨收2736.07万成交额1.37%换手率亏损市盈率(静)2.75亿总股本7.63052周最高-9.06市净率20.00亿流通值3.17052周最低--股息TTM2.69亿流通股121.550历史最高--股息率TTM5.08%振幅0.666历史最低7.434平均价1股每手
关于曼恩凯德生物医疗公司
MannKind Corp是一家生物制药公司。它致力于为糖尿病和肺动脉高压等疾病的患者开发吸入治疗产品并将其商业化。其批准的产品Afrezza（人用胰岛素）吸入粉剂是一种超速效吸入式胰岛素，用于改善成年人糖尿病患者的血糖控制。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。
公司介绍
公司代码MNKD
公司名称曼恩凯德生物医疗
上市日期2004/07/28
发行价格14.00
成立日期1991
CEOMr. Michael E. Castagna, Pharm.D.
所属市场纳斯达克
员工数量414
年结日12-31
公司地址1 Casper Street
城市Danbury
省份康涅狄格州
国家美国
邮编06810
电话1-818-661-5000
董事高管
- 姓名
- 职务
- 年薪
- Michael E. Castagna, Pharm.D.
- Director and Chief Executive Officer
- 706.81万
- Stuart A. Tross, PhD
- Executive Vice President, Chief People and Workplace Officer
- 222.03万
- Lauren M. Sabella
- Executive Vice President and Chief Operating Officer
- 190.63万
- Dr. Burkhard Blank,M.D.
- Executive Vice President, Research and Development and Chief Medical Officer
- --
- Christopher B. Prentiss
- Chief Financial Officer and Principal Accounting Officer
- --
- Dr. David B. Thon, J.D.
- Executive Vice President, General Counsel and Secretary
- 234.30万
- Sanjay R. Singh
- Executive Vice President, Technical Operations
- --
- Dr. James S. Shannon, M.D.,M.R.C.P.
- Chairman of the Board
- 25.56万
- Steven B. Binder
- Director
- 233.51万
- Sabrina Kay
- Independent Director
- 22.17万
- Christine A. Mundkur
- Independent Director
- 22.67万
- Ronald J. Consiglio
- Independent Director
- 24.17万
- Dr. Michael A. Friedman M.D.
- Independent Director
- 22.92万
- Jennifer Grancio
- Independent Director
- 22.17万
- Anthony C. Hooper
- Independent Director
- 23.31万
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
暂无数据